Pharmacokinetic evaluation of colistin sodium

Bibliography

• Michalopoulos A, Falagas ME. Colistin and polymyxin B in critical care. Crit Care Clin 2008;24(2):377-91
   PubMed Web of Science ®Google Scholar
• Li J, Turnidge J, Milne R, In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2001;45:781-5
   PubMed Web of Science ®Google Scholar
• Bergen PJ, Li J, Rayner CR, Nation RL. Colistin methanesulfonate is an inactive prodrug of colistin against pseudomonas aeruginosa. Antimicrob Agents Chemother 2006;50:1953-8
   PubMed Web of Science ®Google Scholar
• Li J, Nation RL, Milne RW, Evaluation of colistin as an agent against multi-resistant gram-negative bacteria. Int J Antimicrob Agents 2005;25(1):11-25
   PubMed Web of Science ®Google Scholar
• Li J, Milne RW, Nation RL, Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother 2004;53(5):837-40
   PubMed Web of Science ®Google Scholar
• Gupta S, Govil D, Kakar PN, Colistin and polymyxin B: a re-emergence. Indian J Crit Care Med 2009;13(2):49-53
   PubMedGoogle Scholar
• Li J, Coulthard K, Milne R, Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother 2003;52(6):987-92
   PubMed Web of Science ®Google Scholar
• Li J, Nation RL, Turnidge JD, Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006;6(9):589-601
   PubMed Web of Science ®Google Scholar
• Conly J, Johnston B. Colistin: the phoenix arises. Can J Infect Dis Med Microbiol 2006;17(5):267-9
   PubMedGoogle Scholar
• Catchpole CR, Andrews JM, Brenwald N, A reassessment of the in-vitro activity of colistin sulphomethate sodium. J Antimicrob Chemother1997;39(2):255-60
   PubMed Web of Science ®Google Scholar
• Leroy P, Decolin D, Nicolas S, Residue determination of two co-administered antibacterial agents – cephalexin and colistin – in calf tissues using high-performance liquid chromatography and microbiological methods. J Pharm Biomed Anal 1989;7:1837-46
   PubMed Web of Science ®Google Scholar
• Sande MA, Kaye D. Evaluation of methods for determining antibacterial activity of serum and urine after colistimethate injection. Clin Pharmacol Ther 1970;11:873-82
   PubMed Web of Science ®Google Scholar
• Owen RJ, Li J, Nation RL, In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2007;59(3):473-7
   PubMed Web of Science ®Google Scholar
• Poudyal A, Howden BP, Bell JM, In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J Antimicrob Chemother 2008;62(6):1311-18
   PubMed Web of Science ®Google Scholar
• Li J, Rayner CR, Nation RL, Hetero-resistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2006;50:2946-50
   PubMed Web of Science ®Google Scholar
• al-Khayyat AA, Aronson AL. Pharmacologic and toxicologic studies with the polymyxins. II. Comparative pharmnacologic studies of the sulfate and methanesulfonate salts of polymyxin B and colistin in dogs. Chemotherapy 1973;19(2):82-97
   PubMed Web of Science ®Google Scholar
• Bergen PJ, Bulitta JB, Forrest A, Pharmacokinetic (PK)/Pharmacodynamic (PD) investigation of colistin (C) against Pseudomonas aeruginosa (Pa) using an in vitro model. Antimicrob Agents Chemother 2010. [Epub ahead of print]
   Google Scholar
• Markou N, Markantonis SL, Dimitrakis E, Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther 2008;30(1):143-51
   PubMed Web of Science ®Google Scholar
• Imberti R, Cusato M, Villani P, Steady-state pharmacokinetics and bronchoalveolar lavage concentration of colistin in critically ill patients after intravenous colistin methanesulphonate administration. Chest 2010. [Epub ahead of print]
   Google Scholar
• Sato H, Ouchi M, Koumi J. Distribution of colistin sulfate in the body. Distribution and metabolism of orally administered colistin sulfate in chickens and pigs. Jpn J Antibiot 1972;25(4):239-45
   PubMedGoogle Scholar
• Ziv G, Nouws JF, van Ginneken CA. The pharmacokinetics and tissue levels of polymyxin B, colistin and gentamicin in calves. J Vet Pharmacol Ther 1982;5(1):45-58
   PubMedGoogle Scholar
• Renard L, Sanders P, Laurentie M. Pharmacokinetics of colistin sulfate administered by intravenous and intramuscular routes in the calf. Ann Rech Vet 1991;22(4):387-94
   PubMedGoogle Scholar
• Li J, Milne RW, Nation RL, Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob Agents Chemother 2003;47(5):1766-70
   PubMed Web of Science ®Google Scholar
• Dudhani RV, Turnidge JD, Coulthard K, Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother 2010;54(3):1117-24
   PubMed Web of Science ®Google Scholar
• Marchand S, Lamarche I, Gobin P, Dose-ranging pharmacokinetics of colistin methanesulphonate (CMS) and colistin in rats following single intravenous CMS doses. J Antimicrob Chemother 2010. [Epub ahead of print]
   Google Scholar
• Escoula L, Coste M, Larrieu G. Bioavailability of erythromycin and colistin in calves. Ann Rech Vet 1981;12(3):321-6
   PubMedGoogle Scholar
• Lin B, Zhang C, Xiao X. Toxicity, bioavailability and pharmacokinetics of a newly formulated colistin sulfate solution. J Vet Pharmacol Ther 2005;28(4):349-54
   PubMed Web of Science ®Google Scholar
• Ziv G, Sulman FG. Passage of polymyxins from serum into milk in ewes. Am J Vet Res 1973;34(3):317-22
   PubMed Web of Science ®Google Scholar
• Tang SS, Gong LJ, He JK, Residue depletion of colistin in swine after intramuscular administration. J S Afr Vet Assoc 2009;80(1):41-4
   PubMedGoogle Scholar
• Chiang SR, Chuang YC, Tang HJ, Intratracheal colistin sulfate for BALB/c mice with early pneumonia caused by carbapenem-resistant Acinetobacter baumannii. Crit Care Med 2009;37(9):2590-5
   PubMed Web of Science ®Google Scholar
• Lu Q, Girardi C, Zhang M, Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa. Intensive Care Med 2010;36(7):1147-55
   PubMed Web of Science ®Google Scholar
• Aoki N, Tateda K, Kikuchi Y, Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. J Antimicrob Chemother 2009;63(3):534-42
   PubMed Web of Science ®Google Scholar
• Scwartz BS, Warren MR, Barkley FA, Microbiological and pharmacological studies of colistin sulfate and sodium colistinmethanesulfonate. Antibiot Annu 1959-1960;7:41-60
   PubMedGoogle Scholar
• Gobin P, Lemaitre F, Marchand S, Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chromatography-tandem mass spectrometry. Antimicrob Agents Chemother 2010;54(5):1941-8
   PubMed Web of Science ®Google Scholar
• Plachouras D, Karvanen M, Friberg LE, Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009;53(8):3430-6
   PubMed Web of Science ®Google Scholar
• Daikos GL, Skiada A, Pavleas J, Serum bactericidal activity of three different dosing regimens of colistin with implications for optimum clinical use. J Chemother 2010;22(3):175-8
   PubMed Web of Science ®Google Scholar
• Li J, Rayner CR, Nation RL, Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 2005;49:4814-15
   PubMed Web of Science ®Google Scholar
• Goodwin NJ, Friedman EA. The effects of renal impairment, peritoneal dialysis, and hemodialysis on serum sodium colistimethate levels. Ann Intern Med 1968;68:984-94
   PubMed Web of Science ®Google Scholar
• Greenberg PA, Sanford JP. Removal and absorption of antibiotics in patients with renal failure undergoing peritoneal dialysis. Tetracycline, chloramphenicol, kanamycin, and colistimethate. Ann Intern Med 1967;66:465-79
   PubMed Web of Science ®Google Scholar
• Froman J, Gross L, Curatola S. Serum and urine levels following parenteral administration of sodium colistimethate to normal individuals. J Urol 1970;103:210-14
   PubMed Web of Science ®Google Scholar
• Berlana D, Llop JM, Fort E, Use of colistin in the treatment of multiple-drug-resistant gram-negative infections. Am J Health Syst Pharm 2005;62(1):39-47
   PubMed Web of Science ®Google Scholar
• Koch-Weser J, Sidel VW, Federman EB, Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970;72:857-68
   PubMedGoogle Scholar
• Le Brun PP, de Boer AH, Mannes GP, Dry powder inhalation of antibiotics in cystic fibrosis therapy. Part 2: inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients. Eur J Pharm Biopharm 2002;54:25-32
   PubMed Web of Science ®Google Scholar
• Le Brun PP, Brimicombe RW, Mannes GP, Advantages of colistin dry powder inhalation. Proof of principle. Pediatr Pulmonol 2000;S20:285
   Google Scholar
• Ratjen F, Rietschel E, Kasel D, Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother 2006;57:306-11
   PubMed Web of Science ®Google Scholar
• Fernandez-Viladrich P, Corbella X, Corral L, Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter baumannii with intraventricular colistin sulfomethate sodium. Clin Infect Dis 1999;28:916-17
   PubMed Web of Science ®Google Scholar
• Gump WC, Walsh JW. Intrathecal colistin for treatment of highly resistant Pseudomonas ventriculitis: case report and review of the literature. J Neurosurg 2005;102:915-17
   PubMed Web of Science ®Google Scholar
• Quinn AL, Parada JP, Belmares J, Intrathecal colistin and sterilization of resistant Pseudomonas aeruginosa shunt infection. Ann Pharmacother 2005;39:949-52
   PubMed Web of Science ®Google Scholar
• Ng J, Gosbell IB, Kelly JA, Cure of multiresistant acinetobacter baumannii central nervous system infections with intraventricular or intrathecal colistin: case series and literature review. J Antimicrob Chemother 2006;58(5):1078-81
   PubMed Web of Science ®Google Scholar
• Markantonis SL, Markou N, Fousteri M, Penetration of colistin into cerebrospinal fluid. Antimicrob Agents Chemother 2009;53(11):4907-10
   PubMed Web of Science ®Google Scholar
• Jimenez-Mejias ME, Pichardo-Guerrero C, Marquez-Rivas FJ, Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis. Eur J Clin Microbiol Infect Dis. 2002;21(3):212-14
   PubMed Web of Science ®Google Scholar